CommercialPrior AuthMedium impact
08.01.01o, Ipilimumab (Yervoy®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
Commercial insurance policy for Ipilimumab (Yervoy®) has been updated with changes to medical necessity criteria, medical coding requirements, and general guidelines. This affects oncology practices that prescribe this cancer immunotherapy drug.
Action Required
By December 29, 2025: Oncology billing teams must review updated medical necessity criteria for Ipilimumab (Yervoy®) prescriptions. Update prior authorization workflows and documentation requirements according to new guidelines. Verify coding practices align with updated medical coding requirements to prevent claim denials.